Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 28.3296
- Book/Share 21.5883
- PB 5.6888
- Debt/Equity 0.7773
- CurrentRatio 0.8179
- ROIC 0.1794
- MktCap 239917066249.0
- FreeCF/Share 8.6273
- PFCF 14.2757
- PE 17.4926
- Debt/Assets 0.3126
- DivYield 0.0326
- ROE 0.3256
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVS | Goldman | Neutral | Sell | -- | $118 | Sept. 12, 2025 |
| Upgrade | NVS | Morgan Stanley | Underweight | Equal Weight | -- | $123 | Aug. 8, 2025 |
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
| Downgrade | NVS | HSBC Securities | Hold | Reduce | -- | -- | Dec. 4, 2024 |
| Downgrade | NVS | BofA Securities | Buy | Neutral | $135 | $130 | Sept. 11, 2024 |
| Downgrade | NVS | Goldman | Buy | Neutral | -- | -- | Sept. 5, 2024 |
| Downgrade | NVS | Jefferies | Buy | Hold | -- | -- | Sept. 3, 2024 |
News
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NYSE:NVS ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas Exane, Research Division Steve Scala - TD Cowen, Research Division Xue Chen - Barclays Bank PLC, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Read More
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Read More
Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Novartis AG (NVS) M&A Call Transcript
Published: October 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NYSE:NVS ) M&A Call October 27, 2025 8:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Robert Baloh Norman Putzki - Global Program Head of Neuroscience Conference Call Participants Sachin Jain - BofA Securities, Research Division Harry Sephton Seamus Fernandez - Guggenheim Securities, LLC, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Read More
Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
Published: October 26, 2025 by: WSJ
Sentiment: Positive
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Read More
Novartis to acquire Avidity Biosciences for about $12B
Published: October 26, 2025 by: New York Post
Sentiment: Neutral
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.
Read More
Novartis Deal Values Avidity Biosciences At $12 Billion
Published: October 26, 2025 by: Barrons
Sentiment: Positive
The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.
Read More
Novartis to acquire Avidity Biosciences for $12 billion
Published: October 26, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.
Read More
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Published: October 26, 2025 by: PRNewsWire
Sentiment: Neutral
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a new company ("SpinCo") Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions SAN DIEGO , Oct. 26, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it has entered into a definitive merger agreement …
Read More
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Published: October 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipeline Expected to unlock multi-billion-dollar opportunities with planned product launches before 2030 Raises expected 2024-2029 sales CAGR for Novartis from +5% to +6%, and bolsters mid-single digit long-term growth As part of the agreement, Avidity will separate its early-stage precision cardiology programs into a new company (“SpinCo”) prior to closing Consideration totals USD 12bn in cash; closing expected in …
Read More
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Published: October 26, 2025 by: CNBC
Sentiment: Positive
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
Read More
Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Read More
Novartis: Assessing The Impact Of Entresto Generics
Published: October 16, 2025 by: Seeking Alpha
Sentiment: Positive
Entresto generics have finally arrived in the U.S. in July, and approximately 9% of Novartis' revenue will be impacted. The growth of other key products and of Entresto in ex-U.S. territories should be enough for mid-single-digit revenue growth rates through the Entresto erosion period. The late-stage pipeline is thin, with few major catalysts between now and 2027, and management continues to guide only bolt-on acquisitions.
Read More
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Read More
3 Reasons Growth Investors Will Love Novartis (NVS)
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
Even the launch of generic versions of heart failure blockbuster Entresto and Trump's threats to cut drug prices won't overshadow the strong performance of Novartis AG's oncology franchise. So, sales of Scemblix, which is rapidly capturing the chronic myeloid leukemia market, reached $298 million for NVS in the second quarter of 2025, an increase of 81.7% year-on-year. Also, I was pleased to see that NVS repurchased $2.71 billion worth of its shares in Q2 2025, a 68% increase year-on-year.
Read More
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Novartis (NVS) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Read More
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Published: September 15, 2025 by: Benzinga
Sentiment: Positive
Monte Rosa Therapeutics Inc. GLUE stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.
Read More
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
Read More
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Published: September 09, 2025 by: Investors Business Daily
Sentiment: Positive
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company for $1.4 billion.
Read More
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883